SCHEMBL3780733

SCHEMBL3780733

NCc1ccccc1-c1cccs1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.61
DPP4 P27487 3/20 0.50
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
ATM Q13315 1/20 0.41
TDO2 P48775 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
PNMT P11086 2/20 0.39
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LTK P29376 1/20 0.38
CDK5 Q00535 1/20 0.38
MST1R Q04912 1/20 0.38
DYRK1A Q13627 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2463750 0.98 LTA4H (0.59) LTA4HDPP4RAB9ANPC1ATM
SCHEMBL7040229 0.85 LTA4H (0.57) LTA4HRAB9ANPC1ATMTDO2
SCHEMBL4845248 0.80 LTA4H (0.61) LTA4HDPP4RAB9ANPC1ATM
SCHEMBL477614 0.80 LTA4H (0.61) LTA4HDPP4RAB9ANPC1ATM
SCHEMBL5023959 0.80 LTA4H (0.66) LTA4HDPP4RAB9ANPC1KDM4E
SCHEMBL6028964 0.80 LTA4H (0.61) LTA4HDPP4RAB9ANPC1ATM
SCHEMBL4846964 0.80 LTA4H (0.61) LTA4HDPP4RAB9ANPC1ATM
SCHEMBL4848749 0.80 LTA4H (0.61) LTA4HDPP4RAB9ANPC1ATM
SCHEMBL995326 0.78 LTA4H (0.55) LTA4HRAB9ANPC1ATMTDO2
SCHEMBL3906600 0.77 LTA4H (0.57) LTA4HDPP4RAB9ANPC1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114380753-A Aryl or heteroaryl substituted quinoxaline-2, 3-diamine compound and antibacterial application thereof 中国医学科学院药物研究所 2022-04-22 CN disclosed
US-20210147427-A1 PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE LEAD DISCOVERY CENTER GMBH (DE) 2021-05-20 US disclosed
WO-2019197549-A1 PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE QURIENT CO., LTD. (KR) 2019-10-17 WO disclosed
EP-2820020-B1 PYRAZOLO-TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2016-04-06 EP disclosed
WO-2013128028-A1 PYRAZOLO - TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN- DEPENDENT KINASE INHINITORS LEAD DISCOVERY CENTER GMBH (DE) 2013-09-06 WO disclosed
EP-2634190-A1 Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors Lead Discovery Center GmbH (DE) 2013-09-04 EP disclosed
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed
CN-1203047-C Biaryl ether derivatives useful as monoamine reuptake inhibitors PFIZER PROD INC (US) 2005-05-25 CN disclosed
CN-1157365-C Monoamine uptake inhibitors for the treatment of CNS disorders �Ʒ� 2004-07-14 CN disclosed
CN-1378527-A Biaryl ether derivatives useful as monoamine reuptake inhibitors PFIZER PROD INC (US) 2002-11-06 CN disclosed
CN-1341094-A Monoamine reuptake inhibitors for treatment of CNS disorders PFIZER PROD INC (US) 2002-03-20 CN disclosed
US-4242474-A A POLYHYDROXY ACRYLIC ESTER REACTED WITH AN ISOCYANATE TERMINATED POLYOXYALKYLENE GLYCOL; BIOPOLYMERS TERUMO CORPORATION (JP) 1980-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 LTA4H 2263/4885DPP4 3267/4885RAB9A 1357/4885
US-20210147427-A1 PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE CDK1, CDK2, CDK15 LTA4H 1834/4885DPP4 1377/4885RAB9A 4072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.